Easy to use, contactless Dual-Mode Ultrasound Technology for high accuracy treatment of Atrial Fibrillation, improving outcomes

Our mission is to radically change the landscape of cardiac ablation.

Our products, based on proprietary ultrasound technology, allow contactless tissue ablation with real-time lesion monitoring, bringing Healium to the forefront of the cardiac ablation market. Our team, backed by scientific and business advisors, includes Dr.

Eckhouse, Chairman, leading medical entrepreneur who has founded >20 companies, and cumulated >1B in exits (Ventor for $325M, Synron and Lumenis both IPO > $1B). Ran Sela, CEO and co-founder, >15-years of medical device development and project management. Dr. Megel, CTO, and co-founder, >25-years in ultrasound-based medical devices.

Now, we are at the top-risk phase of our development journey: the transition from preclinical to clinical studies.

Leveraging an EC investment of 12.75M we can demonstrate the efficacy and safety of our product, establish a manufacturing line and regulatory framework, and access the market as a self-sustained company.